[{"id":"7f7e2c43-583a-4168-9680-7d625fc3f2db","acronym":"","url":"https://clinicaltrials.gov/study/NCT05472610","created_at":"2022-07-25T20:54:31.526Z","updated_at":"2024-07-02T16:36:06.800Z","phase":"Phase 2","brief_title":"Study of Efficacy of BZ019 in Large B-cell Lymphoma","source_id_and_acronym":"NCT05472610","lead_sponsor":"Shanghai Mengchao Cancer Hospital","biomarkers":" IL6 • IL2 • IL10","pipe":" | ","alterations":" CD20 negative","tags":["IL6 • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • BZ019"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 06/04/2021","start_date":" 06/04/2021","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 01/01/2023","study_completion_date":" 01/01/2023","last_update_posted":"2022-07-25"},{"id":"a0eaad27-66db-41b8-9f54-195922d8ae6e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04067414","created_at":"2021-01-18T19:55:37.509Z","updated_at":"2024-07-02T16:36:48.286Z","phase":"Phase 1","brief_title":"Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma","source_id_and_acronym":"NCT04067414","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement • CD20 negative","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • BZ019"],"overall_status":"Unknown status","enrollment":" Enrollment 12","initiation":"Initiation: 06/14/2018","start_date":" 06/14/2018","primary_txt":" Primary completion: 07/31/2020","primary_completion_date":" 07/31/2020","study_txt":" Completion: 12/31/2020","study_completion_date":" 12/31/2020","last_update_posted":"2020-03-17"},{"id":"7f8786d1-59b3-405f-9c9b-cbd9c774d00f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04250324","created_at":"2021-01-18T20:39:15.886Z","updated_at":"2024-07-02T16:36:50.621Z","phase":"Phase 1","brief_title":"Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma","source_id_and_acronym":"NCT04250324","lead_sponsor":"Shanghai Cell Therapy Group Co.,Ltd","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement • CD20 negative","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • BZ019"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 11/19/2019","start_date":" 11/19/2019","primary_txt":" Primary completion: 08/01/2022","primary_completion_date":" 08/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2020-01-31"}]